ArriVent BioPharma (AVBP) Other Accumulated Expenses (2023 - 2026)

ArriVent BioPharma has disclosed Other Accumulated Expenses across 4 years of filings, most recently posting $39000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $39000.0, down 75.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $39000.0 (down 75.78% YoY), and the FY2025 annual result was $18000.0, down 73.13% from the prior year.
• Other Accumulated Expenses came in at $39000.0 for Q1 2026 at ArriVent BioPharma, up from $18000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $161000.0 in Q1 2025 to a low of $18000.0 in Q4 2025.
• The 4-year median for Other Accumulated Expenses is $86000.0 (2024), against an average of $90200.0.
• Across the five-year window, Other Accumulated Expenses surged 335.14% in 2025 and slumped 75.78% in 2026, its largest moves.
• ArriVent BioPharma's Other Accumulated Expenses stood at $62000.0 in 2023, then increased by 8.06% to $67000.0 in 2024, then sank by 73.13% to $18000.0 in 2025, then jumped by 116.67% to $39000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $39000.0 (Q1 2026), $18000.0 (Q4 2025), and $105000.0 (Q3 2025), per Business Quant data.